Recruiting

Therapeutic Strategies

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Code:

NCT04343365

Conditions

Incurable Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Evolutionary Tumor Board (ETB)

Study Details

Brief summary:

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Conditions

Incurable Disease

Study ID

NCT04343365

Start date

May 5, 2020

Status verified date

Mar, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Mar, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
  • Participant must have a life expectancy greater than 3 months
  • Participant must have an ECOG performance status 0-2
  • Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
  • Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion Criteria:

  • None

Study Design

Enrollment

35 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants Reviewed by ETB

Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.

Interventions

Evolutionary Tumor Board (ETB)

The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation

Primary outcome measure

  • ETB developing therapeutic strategies [ Time Frame: Baseline to up to 60 months from end of therapy ]

Central Contacts and Locations

Central contacts

Sara Donadelli

813-745-8111Sara.Donadelli@moffitt.org

Locations

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33613

Contacts

Sara Donadelli

813-745-8111Sara.Donadelli@moffitt.org

Principal Investigator:

Jingsong Zhang, MD

More Information

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Last update posted

Apr 1, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2026-04-01.